Mashup Score:2
Endpoints NewsArticles from: Endpoints News
With atopic dermatitis rivals breathing down Dupixent’s neck, Sanofi and Regeneron on Friday secured a first win in new territory in what Sanofi’s head...
-
Sanofi and Regeneron clear the finish line in an inflammatory esophagus disease, leaving Takeda in the dust By @Nicole_DeFeudis https://t.co/hVdk08PFIL - view on twitter
Mashup Score:2
Endpoints NewsYesterday, the team at All Blue Capital — bent on the takeover of a badly battered Zymeworks — brought in celebrated oncologist, Pulitzer prize-winning...
-
At least these guys at All Blue are making it fun -- All Blue's $733M bid to acquire Zymeworks turns hostile as board battles back — after a biotech celebrity jumps in $ZYME https://t.co/IzPofQSshy - view on twitter
Mashup Score:1
Endpoints NewsThe FDA is tapping the brakes on a Flagship-backed biotech’s R&D efforts to develop a new treatment for blood cancers after a patient died...
-
Flagship's Foghorn, partnered with Merck and Eli Lilly, gets a partial FDA hold after patient death $FHTX -24% https://t.co/EPKaQdfTVP - view on twitter
Mashup Score:6
Endpoints NewsBayer sounds retreat from a $670 million CAR-T pact in the wake of a patient death - 5 days
Mashup Score:6
Two months after Atara Biotherapeutics hit the hold button on its lead CAR-T 2.0 therapy following a patient death, putting the company under the...
-
More on #CART https://t.co/ekTTmxEMg5 - view on twitter
More coverage:
#cart
Mashup Score:5
Endpoints NewsBayer sounds retreat from a $670 million CAR-T pact in the wake of a patient death - 5 days
Mashup Score:5
Two months after Atara Biotherapeutics hit the hold button on its lead CAR-T 2.0 therapy following a patient death, putting the company under the...
-
Regarding the $ATRA retreat, Bayer tells me there is no broad reshuffle going on in cell and gene -- https://t.co/WcMiKm3BGc - view on twitter
Mashup Score:3
Endpoints NewsBayer sounds retreat from a $670 million CAR-T pact in the wake of a patient death - 6 days
Mashup Score:3
Two months after Atara Biotherapeutics hit the hold button on its lead CAR-T 2.0 therapy following a patient death, putting the company under the...
-
Bayer sounds retreat from a $670 million CAR-T pact in the wake of a patient death in PhI $ATRA https://t.co/WcMiKm3BGc - view on twitter
Mashup Score:2
Endpoints NewsFDA commissioner announces new role for Janet Woodcock, downshifting away from drugs - 6 days
Mashup Score:2
New FDA commissioner Rob Califf told staff in a memo yesterday evening that longtime drug center director Janet Woodcock, who’s now serving as Califf’s...
-
FDA commissioner announces new role for Janet Woodcock, downshifting away from drugs https://t.co/0Q70774Ssn - view on twitter
Mashup Score:4
Endpoints NewsInfamous biotech exec Martin Shkreli gets out of prison, hits the street - 7 days
Mashup Score:4
Martin Shkreli, the infamous biotech CEO who made headlines for his jeering assault on a legion of critics in and out of Congress, is...
-
Some stories you follow because it's fun or interesting or necessary. Then there's Martin Shkreli, who's like a bad tattoo you got one drunk night in New Orleans. It just won't go away. https://t.co/gAAHvEuejj - view on twitter
Mashup Score:2
Endpoints NewsFlagship has crafted a new startup out of pieces from a pair of fledglings in the VC’s nest. And a prominent Roche veteran who...
-
Flagship builds a new startup out of pieces from 2 of its biotechs. And a Roche vet leaves to do something new https://t.co/BvdylI6uyo - view on twitter
Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can...
Time for the weekend report, from @AmberTongPW, which now has close to 54K subscribers: Amid monkeypox fears, biotechs spring to action; Moderna’s CFO trouble; Cuts, cuts everywhere; Crafting the right proteins; and more https://t.co/eVHZoRARuO - view on twitter